top of page

News & Featured Coverage

May 6, 2024

Rethinking Mental Health: How Emerging Therapies Are Changing the Game

Rethinking Mental Health: How Emerging Therapies Are Changing the Game

Mar 13, 2024

Supplying Complex, Controversial, And Intercontinental Clinical Trials

Supplying Complex, Controversial, And Intercontinental Clinical Trials

Mar 4, 2024

ALS: how close are we to a cure?

ALS: how close are we to a cure?

Jan 15, 2024

Interviews: Neurological Breakthroughs and Mindful Living: Janet Qi’s PurMinds Revolution

Interviews: Neurological Breakthroughs and Mindful Living: Janet Qi’s PurMinds Revolution

Jan 10, 2024

30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond

30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond

Dec 21, 2023

Wonderland 2023: Pureminds NeuroPharma With Janet Qi

Wonderland 2023: Pureminds NeuroPharma With Janet Qi

Dec 14, 2023

PurMinds Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco

PurMinds Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco

Nov 29, 2023

Cross Time Report: PurMinds Chief Innovation Officer to Speak at the Analytical Cannabis Educational Webinar about Next Generation Psychedelics and the Neurobiology of Neuroplastogens

Cross Time Report: PurMinds Chief Innovation Officer to Speak at the Analytical Cannabis Educational Webinar about Next Generation Psychedelics and the Neurobiology of Neuroplastogens

Nov 9, 2023

PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski, to Chief Scientific Officer and Appoints Pharma Veteran Dr. Max Arella to Scientific Advisory Board

PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski, to Chief Scientific Officer and Appoints Pharma Veteran Dr. Max Arella to Scientific Advisory Board

Nov 7, 2023

Wonderland Conference Miami: Bridging Psychedelics And Overall Wellness

Wonderland Conference Miami: Bridging Psychedelics And Overall Wellness

Nov 7, 2023

PurMinds Triples its Psilocybin-Containing Mushroom Propagation Yields and Increases its Inventory of Dried Psilocybe Cubensis Strains for Supply to Clinical Trials and Authorized Medical Clinics World-Wide

PurMinds Triples its Psilocybin-Containing Mushroom Propagation Yields and Increases its Inventory of Dried Psilocybe Cubensis Strains for Supply to Clinical Trials and Authorized Medical Clinics World-Wide

Oct 25, 2023

Recent Coverage: Psychedelics and health at the forefront for upcoming Wonderland Miami

Recent Coverage: Psychedelics and health at the forefront for upcoming Wonderland Miami

Oct 25, 2023

PurMinds NeuroPharma Chief Innovation Officer to Speak at Wonderland Conference

PurMinds NeuroPharma Chief Innovation Officer to Speak at Wonderland Conference

Oct 11, 2023

PurMinds NeuroPharma Awarded Synthetic Psilocybin API Import Permit from Health Canada to Develop GMP-Compliant Psychedelic Drug Product Formulations for Clinical Trial Supply

PurMinds NeuroPharma Awarded Synthetic Psilocybin API Import Permit from Health Canada to Develop GMP-Compliant Psychedelic Drug Product Formulations for Clinical Trial Supply

Sept 28, 2023

PurMinds Acquires Novel Chemical Entity HDAC6 Inhibitor for Neurological Disorders

PurMinds Acquires Novel Chemical Entity HDAC6 Inhibitor for Neurological Disorders

Sept 8, 2023

PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski to the Scientific Advisory Board

PurMinds Appoints Leading Drug Designer, Dr. Alan Kozikowski to the Scientific Advisory Board

Mar 8, 2022

PsyCap Recap: PurMinds NeuroPharma

PsyCap Recap: PurMinds NeuroPharma

Sept 29, 2021

PurMinds: 'A Neuroscience Biopharma Company With A Robust Psychedelic Strategy'

PurMinds: 'A Neuroscience Biopharma Company With A Robust Psychedelic Strategy'

Jul 7, 2021

PurMinds Completes Initial Strategic Equity Investment in Israeli Psychedelic Drug Company IMIO Life

PurMinds Completes Initial Strategic Equity Investment in Israeli Psychedelic Drug Company IMIO Life
bottom of page